IMWG report on the revised international staging system (R-ISS) for multiple myeloma
The IMWG report on the newly developed revised version of the International Staging System (R-ISS) which incorporates chromosomal abnormalities to develop a more powerful staging system for stratifying myeloma patients.
Multiple myeloma (MM) presents with a heterogeneous clinical outcome, highlighting the need for a simple yet reliable tool to effectively stratify patients. By integrating the established International Staging System (ISS) with the assessment of chromosomal abnormalities (CA) identified through interphase fluorescent in situ hybridisation (FISH) following CD138 plasma cell purification, alongside serum lactate dehydrogenase (LDH) levels, this revised staging system aims to enhance prognostic accuracy for newly diagnosed MM (NDMM) patients.
To support the development of the R-ISS, clinical and laboratory data from 4,445 patients with NDMM, enrolled across 11 international trials, were pooled. This extensive dataset allowed researchers to employ the K-adaptive partitioning algorithm, enabling the identification of the most appropriate subgroups characterised by homogeneous survival rates. By refining the stratification of patients based on these comprehensive criteria, the R-ISS aims to provide healthcare professionals with a powerful tool to guide treatment decisions and improve patient outcomes. This new approach not only enhances our understanding of disease progression but also lays the groundwork for more personalised treatment strategies in the management of multiple myeloma.
Use Case
Type
Source
You might also like
BSH/UKMS good practice paper on Diagnosis and management of smouldering myeloma
Explore the latest guidelines for Smouldering Myeloma care in the British Society for Haematology Good Practice Paper.
BSH GuidelineBSH/UKMS guidelines on the Diagnosis, investigation, and initial treatment of myeloma
These new guidelines, produced by the British Society for Haematology (BSH) and the UK Myeloma Society (UKMS), provide healthcare professionals with guidance on the anti-myeloma management of patients with newly diagnosed myeloma.
Scottish referral guidelines for suspected cancer
The Scottish Referral Guidelines for Suspected Cancer were created to help GPs, the wider primary care team, other clinicians, patients and carers to identify those people who are most likely to have cancer and who therefore require urgent assessment by a specialist.
Other GuidelineIMWG consensus recommendations on imaging in monoclonal plasma cell disorders
The IMWG present recommendations on imaging both in clinical practice and in the trial setting to help standardise the best imaging methods to use as myeloma patients progress through different disease stages.
IMWG GuidelineMY-RADS guidelines for acquisition, interpretation, and reporting of whole-body MRI in myeloma
As whole-body MRI is listed in NICE guidance as the recommended first line imaging in patients with suspected myeloma, this paper outlines a clinical protocol: the Myeloma Response Assessment and Diagnosis System (MY-RADS), for its use and interpretation.
Other GuidelineNICE guidelines on Low back pain and sciatica in over 16s: assessment and management [NG59]
This NICE guideline provides recommendations for non-specialists on assessing and managing low back pain and sciatica.
NICE GuidelineNICE guidelines on Myeloma diagnosis and management [NG35]
These guidelines, produced by the National Institute for Health and Care Excellence (NICE), set out new recommendations for the diagnosis, treatment and care of myeloma patients with the aim of providing consistently excellent patient-focused care within the NHS in England.
NICE GuidelineNICE guidelines on Recognition and referral of suspected cancer [NG12]
This NICE guidance outlines recommendations for children and adults with suspected cancer, including primary care investigations and referral recommendations to secondary care.
NICE GuidelineUKMS and NMSG guidelines for the Investigation of newly detected M-proteins and the management of MGUS
These guidelines, written by the UK Myeloma Society, in conjunction with the Nordic Myeloma Study Group provide guidance for the effective clinical investigation of patients with newly detected paraprotein and the practical management of patients with monoclonal gammopathy of undetermined significance (MGUS).
UKMS Guideline
